These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8211970)

  • 1. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson's disease.
    Kodama H; Meguro Y; Tsunakawa A; Nakazato Y; Abe T; Murakita H
    Tohoku J Exp Med; 1993 Jan; 169(1):59-66. PubMed ID: 8211970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complex formation equilibria of Cu(II) and Zn(II) with triethylenetetramine and its mono- and di-acetyl metabolites.
    Nurchi VM; Crisponi G; Crespo-Alonso M; Lachowicz JI; Szewczuk Z; Cooper GJ
    Dalton Trans; 2013 May; 42(17):6161-70. PubMed ID: 23202417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of disposition behavior and de-coppering effect of triethylenetetramine in animal model for Wilson's disease (Long-Evans Cinnamon rat) with normal Wistar rat.
    Iseki K; Kobayashi M; Ohba A; Miyazaki K; Li Y; Togashi Y; Takeichi N
    Biopharm Drug Dispos; 1992 May; 13(4):273-83. PubMed ID: 1600113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triethylenetetramine pharmacology and its clinical applications.
    Lu J
    Mol Cancer Ther; 2010 Sep; 9(9):2458-67. PubMed ID: 20660601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of triethylenetetramine in plasma of patients by high-performance liquid chromatography.
    Miyazaki K; Kishino S; Kobayashi M; Arashima S; Matsumoto S; Arita T
    Chem Pharm Bull (Tokyo); 1990 Apr; 38(4):1035-8. PubMed ID: 2379276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
    Lu J; Chan YK; Gamble GD; Poppitt SD; Othman AA; Cooper GJ
    Drug Metab Dispos; 2007 Feb; 35(2):221-7. PubMed ID: 17108057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of administered triethylene tetramine dihydrochloride in humans.
    Kodama H; Murata Y; Iitsuka T; Abe T
    Life Sci; 1997; 61(9):899-907. PubMed ID: 9284083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid chromatographic determination of triethylenetetramine in human and rabbit sera based on intramolecular excimer-forming fluorescence derivatization.
    Nakano Y; Nohta H; Yoshida H; Saita T; Fujito H; Mori M; Yamaguchi M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jul; 774(2):165-72. PubMed ID: 12076686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
    Cooper GJ
    Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilson's disease].
    Tanabe R
    Hokkaido Igaku Zasshi; 1996 Mar; 71(2):217-28. PubMed ID: 8641677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes.
    Tremmel R; Uhl P; Helm F; Wupperfeld D; Sauter M; Mier W; Stremmel W; Hofhaus G; Fricker G
    Int J Pharm; 2016 Oct; 512(1):87-95. PubMed ID: 27553779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of triethylenetetramine dihydrochloride in aqueous solution by reversed-phase ion-pairing high performance liquid chromatography and conductivity detection.
    Hansen EB; Rushing LG; Thompson HC
    J Anal Toxicol; 1985; 9(4):167-71. PubMed ID: 4033073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intestinal absorption and urinary excretion of triethylenetetramine for Wilson's disease in rat].
    Kobayashi M; Sugawara M; Saitoh H; Iseki K; Miyazaki K
    Yakugaku Zasshi; 1990 Oct; 110(10):759-63. PubMed ID: 2074531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triethylenetetramine (TETA).
    ; ;
    Toxicol Ind Health; 2023 Apr; 39(4):183-187. PubMed ID: 36941775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Wilson's disease using triethylenetetramine dihydrochloride (TETA)].
    Hauftová D; Körbel J; Jancík F; Kuhr I; Ferenc M
    Cesk Gastroenterol Vyz; 1978 Dec; 32(8):538-9. PubMed ID: 737791
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Two Salts of Trientine in the Treatment of Wilson's Disease.
    Woimant F; Debray D; Morvan E; Obadia MA; Poujois A
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
    Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
    QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The steady state pharmacokinetics of trientine in Wilson disease patients.
    Pfeiffenberger J; Kruse C; Mutch P; Harker A; Weiss KH
    Eur J Clin Pharmacol; 2018 Jun; 74(6):731-736. PubMed ID: 29417175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects.
    Weiss KH; Thompson C; Dogterom P; Chiou YJ; Morley T; Jackson B; Amin N; Kamlin COF
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):665-675. PubMed ID: 34357516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
    Mohr I; Bourhis H; Woimant F; Obadia MA; Morgil M; Morvan E; Merle U; Denk G; Poujois A; Weiss KH
    J Gastroenterol Hepatol; 2023 Feb; 38(2):219-224. PubMed ID: 36331262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.